Vanderwerf v. Smithkline Beecham Corp.

603 F.3d 842, 2010 U.S. App. LEXIS 8703, 2010 WL 1673114
CourtCourt of Appeals for the Tenth Circuit
DecidedApril 27, 2010
Docket08-3218
StatusPublished
Cited by18 cases

This text of 603 F.3d 842 (Vanderwerf v. Smithkline Beecham Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vanderwerf v. Smithkline Beecham Corp., 603 F.3d 842, 2010 U.S. App. LEXIS 8703, 2010 WL 1673114 (10th Cir. 2010).

Opinions

HENRY, Chief Judge.

The plaintiffs, the Vanderwerf family and the estate of William K. Vanderwerf, appeal the district court’s grant of summary judgment to SmithKline Beecham Corporation (“SKB”), the pharmaceutical company who manufactured paroxetine, under the label Paxil, a medication prescribed to the decedent, who later committed suicide. We are unable, however, to overlook the ill-timed filing of the Vanderwerfs’ notice of appeal, because without a timely notice of appeal, we are deprived of jurisdiction to review the merits of the action. As a result of the plaintiffs’ sua sponte withdrawal of their motion for reconsideration, them appeal is from an order entered seven months earlier. We must grant SKB’s motion to dismiss this appeal as untimely filed.

I. BACKGROUND

The Vanderwerfs suffered a tragic loss when their family’s father, William, who suffered from clinical depression, committed suicide in 2003. The family brought suit seeking damages from SKB, the manufacturer of Paxil, which Mr. Vanderwerf had been prescribed to reduce his depression and anxiety. In various claims asserting strict liability, negligence and breach of implied warranty, the complaint alleged that SKB failed to warn or instruct about the risks of Paxil. The Vanderwerfs further alleged that SKB did not adequately warn Mr. Vanderwerfs treating physicians that Paxil increases the risk of suicidal behavior and/or suicide precursors across all psychiatric disorders for adults of all ages. Under this theory, had the treating physicians received such warnings, they would have (1) not prescribed Paxil; (2) monitored Mr. Vanderwerf more closely; and/or (3) warned Mr. Vanderwerf and his family of the increased risk. The Vanderwerfs claimed that had any of these three events taken place, Mr. Vanderwerf would not have committed suicide.

SKB moved for summary judgment, arguing that (1) the court should exclude the testimony of the Vanderwerfs’ proffered witness, Dr. Peter Breggin; (2) without an expert’s testimony the Vanderwerfs cannot methodologically prove general or specific causation; and (3) the Vanderwerfs could not demonstrate proximate causation because, had SKB provided additional warnings to the treating physicians, the doctors would not have changed them course of treatment.

On January 9, 2008, the district court, in a thirty-one page order, granted summary judgment to SKB. The court first noted that because suicidality occurs in many people who are not exposed to Paxil or any other medicine, the plaintiffs needed to present expert testimony to meet their burden of proving medical causation that Paxil can cause suicide (general causation) and that Paxil more likely than not caused Mr. Vanderwerfs suicide (specific causation). The court excluded Dr. Breggin’s testimony “[f]or substantially the reasons stated in [SKB’s motion to exclude Dr. Breggin’s testimony and its reply brief in support of that motion].” 1 Aplts’ App. vol. [844]*844XII, at 2354 (Dist. Ct. Order, filed Jan. 9, 2008).

As to general causation, the district court also found that (1) Dr. Breggin did not put forth an accepted methodology for determining general causation (i.e., that Paxil can cause suicide); (2) failed to account for the substantial body of evidence indicating no causal link between Paxil and suicide or suicidal behavior in adults, particularly those beyond the age of thirty; and (3) did not sufficiently distinguish statistical “association” from causation. Id.

The court similarly concluded that because Dr. Breggin could not testify, the Vanderwerfs could not establish that Paxil more likely than not caused Mr. Vanderwerfs suicide (i.e., specific causation). Id. at 2358. The court stated that even given SKB expert Dr. John Kraus’s testimony, any conclusion that Paxil more likely than not caused Mr. Vanderwerfs suicide “would be sheer speculation.” Id. Because the Vanderwerfs offered no evidence of specific causation aside from the testimony of Dr. Breggin, the court sustained SKB’s motion for summary judgment on this alternative ground.

Finally, the district court determined that even had the Vanderwerfs established general and specific causation, they could not establish proximate causation. Under Kansas’s learned intermediary doctrine,2 the court first assumed that SKB should have provided labeling and warnings that (1) Paxil increased the risk of suicidal behavior and (2) Paxil increased the risk of suicide precursors such as activation, overstimulation, anxiety, insomnia and agitation. Additionally, the court assumed that Paxil could have provided a warning consisting of information that SKB disclosed in 2006 in the DHCP letter that there existed a “possible increase in risk of suicidal behavior” in adults who took Paxil. Aplts’ App. at 2345.

The court acknowledged the Vanderwerfs’ argument that if there had been a warning that Paxil increased the risk of suicide in adults, Dr. John Crane, Mr. Vanderwerfs treating physician at the time of the suicide, would have passed along the additional warning and “watched [Mr.Vanderwerf] considerably closer.” Id. at 2364. Dr. Crane testified that he might “not even have used [Paxil] in a certain individual,” had he known of the risks involved. Id. But given the positive results [845]*845Mr. Vanderwerf had shown while on Paxil, however, the court understood that the treating physicians would still prescribe Paxil for Mr. Vanderwerf. Thus, the court concluded that the argument that the treating physicians “may not have used [Paxil] in a certain individual” was speculative and did not raise a genuine issue of fact as to the prescription for Mr. Vanderwerf.

In granting summary judgment to SKB, the district court concluded that “[speculation about how this tragedy might have been avoided is absolutely understandable and perhaps inevitable, but [the Vanderwerfs] cannot escape summary judgment based on speculation.” Id. at 2367.

On January 17, 2008, eight days after the district court granted summary judgment to SKB, the Vanderwerfs filed a Rule 59(e) Motion to Reconsider arguing that the district court incorrectly granted summary judgment based on the flawed determination that the Vanderwerfs had presented insufficient evidence of general, specific and proximate causation. Despite the passage of about seven months, the district court did not act on the motion to reconsider. Counsel for the Vanderwerfs report they telephoned the district court judge’s chambers and spoke to a law clerk on two occasions, each time inquiring into the status and likelihood of a ruling on the motion. But on August 8, 2008, counsel decided to file a notice of withdrawal of the Rule 59 motion, and also filed a Notice of Appeal. Unfortunately, the timing of this Notice of Appeal deprives this court of jurisdiction.

II. DISCUSSION

The Vanderwerfs argue that their withdrawal of their Rule 59(e) motion and their filing of a notice of appeal satisfied the Federal Rules of Appellate Procedure’s requirements. We disagree.

The Vanderwerfs withdrawal of their Rule 59(e) motion and filing of a notice of appeal do not satisfy the Federal Rules of Appellate Procedure’s requirements

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Valles v. State of Utah
Tenth Circuit, 2025
Bunn v. Perdue
966 F.3d 1094 (Tenth Circuit, 2020)
Maureen Davis v. Wells Fargo Home Mortgage
Court of Appeals of Tennessee, 2018
Melina v. Pollard
654 F. App'x 939 (Tenth Circuit, 2016)
Worcester v. Springfield Terminal Railway Co.
827 F.3d 179 (First Circuit, 2016)
Losee v. Gallegos
613 F. App'x 750 (Tenth Circuit, 2015)
Merrell v. Allred
565 F. App'x 692 (Tenth Circuit, 2014)
Ning Lu v. Kendall
561 F. App'x 751 (Tenth Circuit, 2014)
Grosvenor v. Qwest Corporation
733 F.3d 990 (Tenth Circuit, 2013)
Mais v. Gulf Coast Collection Bureau, Inc.
944 F. Supp. 2d 1226 (S.D. Florida, 2013)
De Leon v. Marcos
659 F.3d 1276 (Tenth Circuit, 2011)
Copar Pumice Co., Inc. v. Morris
639 F.3d 1025 (Tenth Circuit, 2011)
Matthews v. LaBarge, Inc.
407 F. App'x 277 (Tenth Circuit, 2011)
United States v. Reed
410 F. App'x 107 (Tenth Circuit, 2010)
Lester v. K Mart Corporation
387 F. App'x 879 (Tenth Circuit, 2010)
United States v. Akers
384 F. App'x 758 (Tenth Circuit, 2010)
Vanderwerf v. Smithkline Beecham Corp.
603 F.3d 842 (Tenth Circuit, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
603 F.3d 842, 2010 U.S. App. LEXIS 8703, 2010 WL 1673114, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vanderwerf-v-smithkline-beecham-corp-ca10-2010.